← Back to Search

Cases (CLOSED) for Sickle Cell Disease

N/A

Waitlist Available

Led By Elliott Vichinsky, MD

Research Sponsored by UCSF Benioff Children's Hospital Oakland

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be between 18 and 65 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up within 2 months of signing informed consent.

Awards & highlights

No Placebo-Only Group

Summary

Sickle cell disease (SCD), also known as sickle cell anemia, is an inherited blood disease that can cause intense pain episodes and may lead to organ failure. Preliminary studies have shown that adults with SCD may have brain abnormalities that contribute to problems with cognitive functioning, including attention and memory difficulties. This study will use brain magnetic resonance imaging (MRI) and neuropsychological testing to examine the differences in cognitive functioning in adults with SCD and adults without SCD. 212 subjects participated in this cross-sectional study consisting of screening questionnaires, a neuropsychological testing battery, and MRI testing. Enrollment into this study ended in May 2008.

Eligible Conditions

Sickle Cell Disease
Sickle Cell Anemia

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ within 2 months of informed consent

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~within 2 months of informed consent

This trial's timeline: 3 weeks for screening, Varies for treatment, and within 2 months of informed consent for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Wechsler Adult Intelligence Scale (WAIS)-III Performance IQ

Secondary study objectives

Participants With Brain Lacunae as Measured by Clinical MRI

Volume of Total Cortical Gray Matter as Measured by Volumetric MRI.

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups

Experimental Treatment

Group I: Controls (CLOSED)Experimental Treatment2 Interventions

These are persons that do not have sickle cell disease (confirmed by hemoglobin electrophoresis); matched to cases by age, gender, and education level

Group II: Cases (CLOSED)Experimental Treatment2 Interventions

These are patients diagnosed with sickle cell disease (confirmed by hemoglobin electrophoresis).

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

NP Battery

2004

N/A

~220

MRI

2009